At LMBRI, we help evaluate new drugs during clinical studies for our clients and partners. Under the current FDA draft guidance, some studies require the evaluation of drug products in trial participants who have uremic pruritus with impaired renal (or kidney) function.
Read more
One of our leading Asian multinational partners developed a microarray technology and locally commercialized a product for high throughput miRNA screening that improved the sensitivity, reproducibility, and quality of miRNA detection.
Read more
A small biotechnology company focused on oncology has a leading candidate for the treatment of Glioblastoma. Minerval® has been developed over many years and is the company’s first potential therapeutic product. It employs a novel mechanism of action (MOA).
Read more
U.S. Headquarters
360 Massachusetts Avenue,
Suite 203, Acton,
MA 01720, USA